Centocor, founded in 1979 and headquartered in Horsham, PA, in 1999 became a wholly owned subsidiary of Johnson and Johnson.

Centocor's focus is on finding new treatments to improve the lives of people living with immune-related conditions in the areas of rheumatology, gastroenterology, dermatology and pulmonology.

The company's leading biologic is:

Remicade (infliximab). The first biologic of its kind on the market, Remicade blocks the activity of a specific protein identified as an underlying cause of a number of autoimmune diseases, including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

*Information above taken from materials provided by Centocor.